LAURA

NCT03521154 📎

Regimen

Experimental
osimertinib consolidation
Control
placebo

Population

Unresectable stage III EGFR-mut NSCLC post-CRT

Key finding

mPFS 39.1 vs 5.6 mo, HR 0.16 (0.10-0.24); redefined SoC post-CRT in EGFR-mut III

Source: PMID 38828946

Timeline

  • Enrollment start: 2018-07-19 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.200)
  • CSCO NSCLC 2025 ⚠️ OCR source